Linked Life Data

19543951

Source:http://linkedlifedata.com/resource/pubmed/id/19543951

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-8-24
pubmed:abstractText
We prospectively evaluated the safety and efficacy of the anti-CD20 chimeric monoclonal antibody rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. Seven patients were treated with 375 mg/m(2) rituximab weekly for 4 consecutive weeks. Rituximab was well tolerated with no severe toxicity observed during treatment. At 1 year, 3 patients showed a partial response to rituximab therapy, 3 had stable disease, and 1 had progressive disease. Rituximab allowed a reduction in the dose of steroids in 4 patients. Responsive manifestations included mild to moderate skin and oral lesions, and immune hemolytic anemia, and thrombocytopenia. Severe manifestations involving the skin, fascia, and eye did not respond to treatment. These observations suggest that rituximab therapy may be effective for select patients with corticosteroid-refractory chronic GVHD that is not advanced.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1865-3774
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
253-60
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19543951-Adrenal Cortex Hormones, pubmed-meshheading:19543951-Adult, pubmed-meshheading:19543951-Antibodies, pubmed-meshheading:19543951-Antibodies, Monoclonal, pubmed-meshheading:19543951-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:19543951-Chronic Disease, pubmed-meshheading:19543951-Female, pubmed-meshheading:19543951-Graft vs Host Disease, pubmed-meshheading:19543951-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:19543951-Humans, pubmed-meshheading:19543951-Immunologic Factors, pubmed-meshheading:19543951-Male, pubmed-meshheading:19543951-Middle Aged, pubmed-meshheading:19543951-Prospective Studies, pubmed-meshheading:19543951-Transplantation, Homologous, pubmed-meshheading:19543951-Treatment Outcome, pubmed-meshheading:19543951-Young Adult
pubmed:year
2009
pubmed:articleTitle
Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease.
pubmed:affiliation
Center for Cellular and Molecular Medicine, Kyushu University Graduate School of Medical Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan. tteshima@cancer.med.kyushu-u.ac.jp
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II